Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
06833 Sinco Pharmaceuticals
0.228
-0.015-6.17%
Symbol
06833
Company Name
Sinco Pharmaceuticals
ISIN
KYG8154Y1052
Listing Date
03/10/2016
Establishment Date
03/16/2015
Registration
Cayman Islands
Chairman
Xiangbin Huang
Secretary
Yunlu\lijianwei Peng
Audit Institution
Ernst & Young accounting firm
Company Category
Overseas registration of Mainland Individuals control
Registered Office
PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of Business
Room 2403, wing on centre, 111 Connaught road central, Hong Kong
Fiscal Year Ends
12-31
Employees
120
Market
Hong Kong motherboard
Phone
+852 2960 9692
Fax
+852 2960 1633
Email
sinco-pharm@sinco-pharm.cn
Business
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
Profile
As a leading service provider in marketing, promotion and channel management, with rich experience in the distribution of imported pharmaceuticals, the Group focuses on blood products and provides integrated marketing, promotion and channel management services for overseas small and medium-sized pharmaceutical manufacturers on the basis of a marketing and promotion network covering the whole of China. The Group's products are imported from well-known overseas drugmakers, and the product portfolio mainly covers blood products and prescription drugs such as anti-infective drugs. The marketing and promotion services provided by the Group include: coordinating and cooperating with overseas pharmaceutical manufacturers to carry out import registration ╱ re-registration and other regulatory requirements; formulating customized marketing and marketing strategies based on product treatment areas, product characteristics, regulatory environment, market demand and other commercial factors; selecting, appointing and managing third-party service promoters Organize academic conferences, lectures, seminars and other promotional activities; and communicate to physicians about the medical uses and efficacy of the Group's products. The channel management services provided by the Group include: product customs clearance and inspection; cooperation with third parties to carry out logistics and distribution work; participation in bidding; confirmation of purchase orders, product delivery and collection work of third-party commercial pharmaceutical distribution companies; collection and analysis of sales data; and management and improvement of inventory in commercial distribution channels. The Group's product portfolio covers blood products and anti-infective drugs. We select high-quality products from overseas markets to make up for the unmet pharmaceutical demand in the domestic market, and with their excellent clinical effects, we ensure that they have strong growth potential in China's pharmaceutical industry.
Company Overview
Xingke Rong Pharmaceutical Holdings Co., Ltd. mainly provides marketing, promotion and channel management (MPCM) services in the pharmaceutical industry of the people's Republic of China. The company provides comprehensive MPCM services to small and medium-sized overseas pharmaceutical manufacturers that do not have independent marketing and promotion capabilities in China. Its main product is human serum albumin injection. The product is a human serum albumin produced by Octapharma for the treatment of hypovolemic and hypovolemic shock, abnormally high intracranial pressure, edema and ascites, as well as the prevention and treatment of hypoalbuminemia and neonatal hyperbilirubinemia. In addition, its products include Ankexin, McDonnell, Elsaif, Tate and Torot and so on.
CEO: Xiangbin Huang
Market: Hong Kong motherboard
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...